FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia.

doi:10.1158/0008-5472.CAN-25-0349

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia.

Cancer research - 16 Jan 2026

Zwick Melissa, Zinkel Bastian, Spohr Corinna, Rückert Tamina, Halbach Sebastian, Shoumariyeh Khalid, Scheid Jonas, Baur Anna-Sophia, Braun Lukas M, Angel Moritz, Michaeli Elisa, Todkar Abhijeet, Nelde Annika, Märklin Melanie, Holzmayer Samuel J, Dicks Severin, Boerries Melanie, Duquesne Sandra, Schlaak Alexandra Emilia, Otto-Mora Patricia, Bengsch Bertram, Schiff Marcel, Kissel Sandra, Selle Michael, Follo Marie, Altmann Heidi, Kunadt Desiree, Illert Anna-Lena, Walz Juliane S, Walz Gerd, Duyster Justus, Schetelig Johannes, Brummer Tilman, Zeiser Robert, Köhler Natalie

Abstract excerpt

FMS-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD) mutations are frequent in acute myeloid leukemia (AML) and are associated with a high risk of relapse. CKLF-like MARVEL transmembrane domain containing member 6 (CMTM6) stabilizes PD-L1 surface expression and modulates tumor immunity in solid cancer. In this study, we found a role for FLT3-induced CMTM6 in hematologic malignancies. FLT3 drove CMTM6...

Read the complete abstract on PubMed

Topics

Animals
Humans
Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

fms-Like Tyrosine Kinase 3

MARVEL Domain-Containing Proteins

Mice

Tumor Escape

Chemokines

B7-H1 Antigen

Myelin Proteins

Cell Line, Tumor

Tandem Repeat Sequences

Mutation

Source

Open in PubMed

Identifiers

PMID: 41043134
DOI: 10.1158/0008-5472.CAN-25-0349

Genes

FLT3
CMTM6
CKLF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia.PMID 41043134Read ↗

Suppression of tumor/host intrinsic CMTM6 drives anti-tumor cytotoxicity in a PD-L1 independent mannerSemantic proximity Read ↗

Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemiaSemantic proximity Read ↗

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironmentSemantic proximity Read ↗

The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemiaSemantic proximity Read ↗

MLLT6 maintains PD‐L1 expression and mediates tumor immune resistanceSemantic proximity Read ↗

Targeting Immune Signaling Pathways in Graft-Versus-Host Disease; A Signaling-Centric Review of Future Therapeutic StrategiesSemantic proximity Read ↗

Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses.Semantic proximity Read ↗

Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.Semantic proximity Read ↗

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancersSemantic proximity Read ↗

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1lSemantic proximity Read ↗

FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.Semantic proximity Read ↗

GNF-7, a novel FLT3 inhibitor, overcomes drug resistance for the treatment of FLT3‑ITD acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.